WAY 170523 is a potent and selective inhibitor of matrix metalloprotease MMP-13 (Collagenase-3), expressed in the skeleton during embryonic development, and sometimes highly overexpressed in human carcinomas and in chondrocytes and synovial cells in rheumatoid arthritis and osteoarthritis. Mutations in the MMP-13 gene has been shown to cause metaphyseal anadysplasia (MANDP). WAY 170523 has an IC50 of 17 nM for MMP-13 and showed >5800-, 56-, and >500-fold selectivity against MMP-1, MMP-9, and TACE (TNFα converting enzyme), respectively.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
Sold for research purposes under agreement from Pfizer Inc.
Other Notes
This compound was developed by Pfizer for Cytoskeleton & Extracellular Matrix research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.